<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477281</url>
  </required_header>
  <id_info>
    <org_study_id>E01-TEU-VEN-08-10</org_study_id>
    <nct_id>NCT01477281</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon</brief_title>
  <official_title>A Clinical Multicenter, Phase III, Prospective, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratório Teuto Brasileiro S/A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratório Teuto Brasileiro S/A</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate the effectiveness of the safety of Daflon in decreasing symptoms
      resulting from chronic venous insufficiency when compared with Daflon.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &quot;A clinical multicenter, phase III, prospective, randomized, double-blind, comparative study
      to evaluate the efficacy and tolerability of Venaflon use in reducing the symptoms caused by
      chronic venous insufficiency when compared with Daflon.&quot;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improves the symptoms of chronic venous insufficiency with classification CEAP 0-3</measure>
    <time_frame>30 days</time_frame>
    <description>To evaluate the efficacy of Venaflon compared with Daflon in the improves of symptomatic treatment of chronic venous insufficiency with classification CEAP 0-3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify adverse events, as well as their frequency and causality related to study medication.</measure>
    <time_frame>30 days</time_frame>
    <description>The secondary outcome measure will be to evaluate the tolerability of Venaflon in the symptomatic treatment of chronic venous insufficiency with classification CEAP 0-3.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Chronic Venous Insufficiency</condition>
  <condition>Disease</condition>
  <arm_group>
    <arm_group_label>Venafon (Diosmin and Hesperidin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daflon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daflon</intervention_name>
    <description>Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).</description>
    <arm_group_label>Venafon (Diosmin and Hesperidin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venaflon (Diosmin and Hesperidin)</intervention_name>
    <description>Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).</description>
    <arm_group_label>Daflon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of any ethnic group, both sexes and aged at least 18 years and a maximum of
             65 years

          -  Women and men of childbearing age who agree to use acceptable contraception throughout
             the study.

          -  Be patient with chronic venous insufficiency of lower limbs varicose comDiagnostico
             clinical CEAP 0-3 by CEAP

          -  Presence of at least 23 symptoms (pain, heaviness and discomfort, symptoms of heat and
             burning sensation in the legs) in the lower limbs, with a score equal to or greater
             than 4, as measured by visual analog scale

          -  Being the 7 days without any medication or treatment related to the venous system.

          -  Patients able to make proper use of medication

          -  Patients who consent to participate in the study by signing the Instrument of Consent.

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Women who are breastfeeding

          -  Women and men of childbearing age who do not accept to use acceptable contraception
             throughout the study

          -  Patients under 18 or over 65 years

          -  Patients with a history of hypersensitivity to any component of the formula

          -  Presence of signs and symptoms of different conditions of venous disease to justify
             the pain or swelling

          -  Use of elastic compression in the last two weeks

          -  Venous obstruction of the lower limbs

          -  Patients who have previously used or Venaflon Daflon and did not benefit;

          -  Deep vein thrombosis in the last 6 months before entering the study;

          -  Use of diuretics in the last 4 weeks

          -  Previous venous surgery

          -  Patients with renal and liver failure

          -  Patients with gastritis or gastric ulcer

          -  Patients with blood clotting disorders

          -  Any condition which in the opinion of the physician researcher is significant and can
             make the patient unsuitable for study or you can place it under additional risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>November 18, 2011</last_update_submitted>
  <last_update_submitted_qc>November 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic venous insufficiency</keyword>
  <keyword>Daflon</keyword>
  <keyword>Venaflon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

